Home » Stocks » CDXS

Codexis, Inc. (CDXS)

Stock Price: $18.95 USD 0.77 (4.24%)
Updated May 18, 2021 1:36 PM EDT - Market open
Market Cap 1.18B
Revenue (ttm) 72.42M
Net Income (ttm) -25.43M
Shares Out 64.29M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE 138.89
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $18.95
Previous Close $18.18
Change ($) 0.77
Change (%) 4.24%
Day's Open 17.83
Day's Range 17.80 - 19.27
Day's Volume 217,512
52-Week Range 10.28 - 29.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual inves...

21 hours ago - GlobeNewsWire

Codexis (CDXS) delivered earnings and revenue surprises of 30.00% and 21.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Total Revenue up 23% and Product Revenue Doubles Year over Year

1 week ago - GlobeNewsWire

REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarte...

3 weeks ago - GlobeNewsWire

With the trading day about halfway over, the broad markets were pulling back. All the major averages were reeling, especially the Nasdaq, on concerns over the global semiconductor shortage.

Other stocks mentioned: AZN, BMBL, MCD, MSFT, CCI, IFF, MSI ...
1 month ago - 24/7 Wall Street

A Relative Strength Rating upgrade for Codexis shows improving technical performance. Will it continue?

2 months ago - Investors Business Daily

Shares of Codexis (NASDAQ:CDXS) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 500.00% year over year to ($0.06), which beat the estimate o...

2 months ago - Benzinga

Strong Product Revenue Momentum in Second Half of 2020 Drives Company's Seventh Consecutive Year of YOY Revenue Growth

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investme...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial...

3 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, announced today it will be expanding its operations into a new 36,000 square fo...

3 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of...

3 months ago - GlobeNewsWire

REDWOOD CITY, Calif. and HOFFMANN ESTATES, Ill., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Tate...

4 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 4,285,715 sh...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of share...

5 months ago - GlobeNewsWire

C ombine s Codexis' R&D and commercialization platform with Casdin Capital 's investment expertise to invest in and support innovative early stage life science and synthetic biology technology companies

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate at three upcoming virtual investme...

6 months ago - GlobeNewsWire

Codexis, Inc. (CDXS) CEO John Nicols on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Codexis (CDXS) delivered earnings and revenue surprises of 37.50% and 22.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after mark...

6 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual investment ...

8 months ago - GlobeNewsWire

R&D revenue from two customers helped the business to offset weakness from the coronavirus pandemic.

9 months ago - The Motley Fool

Codexis, Inc. (CDXS) CEO John Nicols on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after m...

9 months ago - GlobeNewsWire

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Has the next biotech unicorn just been minted? Two California firms are focused on a radical new way of writing DNA to create everything from COVID-19 antibodies to high-density data storage.

10 months ago - Forbes

Partnership targets accelerating the commercialization of enzymatic DNA synthesis: Codexis invests cash and protein engineering for equity stake in Molecular Assemblies Partnership targets accelerating ...

10 months ago - GlobeNewsWire

REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new ind...

11 months ago - GlobeNewsWire

First enzymes will target NGS-based diagnostics, RNA-directed viral diagnostics and RNA manufacturing First enzymes will target NGS-based diagnostics, RNA-directed viral diagnostics and RNA manufacturing

11 months ago - GlobeNewsWire

The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.

11 months ago - The Motley Fool

Codexis, Inc. (CDXS) CEO John Nicols on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

REDWOOD CITY, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as S...

1 year ago - GlobeNewsWire

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

The small-cap stock has been cut in half in the last year. Is a $650 million market cap too good to pass up?

1 year ago - The Motley Fool

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies Partnership to leverage ...

1 year ago - GlobeNewsWire

The company expects a fourth straight year of stagnant product revenue -- and declining gross margin, to boot. Those are noteworthy red flags for investors.

1 year ago - The Motley Fool

The enzyme engineering company reported disappointing full-year 2019 operating results.

1 year ago - The Motley Fool

Codexis, Inc. (CDXS) CEO John Nicols on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Codexis (CDXS) delivered earnings and revenue surprises of -66.67% and -11.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

The stock has tumbled to start 2020. Can the next business update provide any relief to shareholders?

1 year ago - The Motley Fool

The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.

1 year ago - The Motley Fool

CHONGQING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.’s (SZSE: 300363) fermentation...

1 year ago - GlobeNewsWire

REDWOOD CITY, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globall...

1 year ago - GlobeNewsWire

REDWOOD CITY, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT4TM DNA li...

1 year ago - GlobeNewsWire

This favorite of institutional shareholders remains off the radars of most retail investors.

1 year ago - The Motley Fool

REDWOOD CITY, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United State...

1 year ago - GlobeNewsWire

Despite nearly meeting its full-year 2019 product revenue guidance after just three quarters, the company didn't raise guidance. What does that mean?

1 year ago - The Motley Fool

Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Codexis, Inc. (CDXS) CEO John Nicols on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Codexis (CDXS) delivered earnings and revenue surprises of 166.67% and 32.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About CDXS

Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherape... [Read more...]

Industry
Biotechnology
IPO Date
Apr 22, 2010
Stock Exchange
NASDAQ
Ticker Symbol
CDXS
Full Company Profile

Financial Performance

In 2020, Codexis's revenue was $69.06 million, an increase of 0.87% compared to the previous year's $68.46 million. Losses were -$24.01 million, 101.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Codexis stock is "Strong Buy." The 12-month stock price forecast is 27.50, which is an increase of 45.12% from the latest price.

Price Target
$27.50
(45.12% upside)
Analyst Consensus: Strong Buy